Dodge & Cox Has $3.05 Billion Stock Position in GSK PLC Sponsored ADR $GSK

Key Points

• Dodge & Cox increased its stake in GSK PLC by 14.9%, owning approximately 78.65 million shares valued at $3.05 billion, making it the company's 18th largest holding.
• GSK recently reported earnings per share of $1.23, beating estimates, with a revenue of $10.64 billion for the quarter, reflecting a 1.3% increase year-over-year.
• The company announced a quarterly dividend of $0.4206 per share, representing a 4.2% yield, despite a debt-to-equity ratio of 1.07.

Dodge & Cox raised its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 14.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 78,651,833 shares of the pharmaceutical company's stock after buying an additional 10,210,921 shares during the period. GSK accounts for 1.7% of Dodge & Cox's holdings, making the stock its 18th largest holding. Dodge & Cox owned approximately 3.81% of GSK worth $3,046,972,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in GSK. Voloridge Investment Management LLC boosted its position in GSK by 1,360.4% in the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock valued at $73,222,000 after buying an additional 2,016,795 shares in the last quarter. Woodline Partners LP acquired a new stake in GSK in the fourth quarter valued at approximately $36,665,000. Miller Howard Investments Inc. NY boosted its position in GSK by 138.4% in the first quarter. Miller Howard Investments Inc. NY now owns 1,646,791 shares of the pharmaceutical company's stock valued at $63,797,000 after buying an additional 955,891 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its position in GSK by 68.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 2,237,034 shares of the pharmaceutical company's stock valued at $75,656,000 after buying an additional 907,068 shares in the last quarter. Finally, Kahn Brothers Group Inc. acquired a new position in shares of GSK during the fourth quarter worth $29,921,000. Institutional investors and hedge funds own 15.74% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on GSK shares. Berenberg Bank restated a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Hsbc Global Res upgraded GSK to a "strong sell" rating in a report on Monday, April 28th. Finally, Wall Street Zen upgraded shares of GSK from a "hold" rating to a "buy" rating in a report on Sunday, August 3rd. Seven research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, GSK presently has a consensus rating of "Reduce" and a consensus price target of $37.38.

GSK Price Performance

GSK stock opened at $40.1450 on Friday. The firm has a market cap of $81.80 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 1.74 and a beta of 0.51. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.67. The company's fifty day simple moving average is $38.34 and its 200 day simple moving average is $38.11.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to analyst estimates of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. GSK's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.2%. GSK's dividend payout ratio is currently 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.